MD Anderson tops $2.5 million at A Conversation With a Living Legend® Washington, D.C., honoring Ken Burns
WASHINGTON, D.C. ― Award-winning filmmaker Ken Burns, often known as “America’s biographer,” was honored at A Conversation With a Living Legend® Washington, D.C., April 22 at The John F. Kennedy Center for the Performing Arts. The event raised $2.5 million for The University of Texas MD Anderson Cancer Center, with proceeds supporting cancer research and patient programs at the nation’s No. 1 hospital for cancer care. A portion of...
AACR: New CAR T cell therapy benefits patients with advanced thyroid cancers
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress...
1,400+ West Texans support MD Anderson at 39th Polo on the Prairie
MIDLAND ― The University of Texas MD Anderson Cancer Center presented its annual Polo on the Prairie fundraising event on April 26 in West...
AACR: HER2 targeted therapy shows promise in previously treated lung cancers
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
These cancers are associated with resistance to standard therapies and a very poor prognosis. As an oral pill, zongertinib would be a more convenient option for patients. Trial data prompted a priority review by the Food and Drug Administration (FDA) earlier this year and sparked a...
These cancers are associated with resistance to standard therapies and a very poor prognosis. As an oral pill, zongertinib would be a more convenient option for patients. Trial data prompted a priority review by the Food and Drug Administration (FDA) earlier this year and sparked a...
AACR: Topical gel relieves painful skin rash side effect caused by targeted therapy for colorectal cancer
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life...
AACR: First-in-class covalent Werner helicase inhibitor shows clinical proof-of-concept in Phase I trial
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other DNA...
AACR: Olaparib and pembrolizumab combination shows early promise in molecularly selected, tumor-agnostic trial
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1...
AACR: Researchers share promising results from MD Anderson clinical trials
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of Texas...
AACR: Five MD Anderson researchers honored with 2025 Scientific Achievement Awards
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and honors at...
AACR: MD Anderson’s John Weinstein elected Fellow of the AACR Academy
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/...
Making Cancer History® Seminar returns to Midland
MIDLAND ― Experts from The University of Texas MD Anderson Cancer Center presented the Making Cancer History® Seminar and Luncheon yesterday...